Turna Ray
Turna Ray has been covering the personalized medicine and molecular diagnostics industries for GenomeWeb since 2006. She closely tracks the evolving regulatory, reimbursement, and business environment for precision medicine products.

Articles Authored by Turna Ray
The company is offering combined germline and somatic cancer testing, and sharing patients' variants identified through that testing in a new research registry.
The Right Drug Dose Now Act seeks to address many of the barriers that have hindered integration of pharmacogenomic information into mainstream care.
Invitae Launches Ciitizen Genome Information Management Platform at JPM
The company believes the platform will expedite its longstanding goal of amassing genomic and other information from patients through their lifespan to fuel discoveries and improve care.
The company plans to launch a polygenic risk score, a germline-somatic test platform, and LDT and kitted tests for disease monitoring and therapy selection.
Labs Ask Medicare Contractor to Refine Coverage Policy for 'Comprehensive' NGS Cancer Testing
Premium
National Government Services' proposal to broaden coverage of large sequencing panels for solid tumor patients is positive but may need clarification to ensure appropriate patient care.
EU IVDR Implementation Woes Could Severely Limit Cancer Companion Test, Precision Therapy Access
Premium
The EC has stuck with its timeline to implement the new regulations in eight months, raising concerns for cancer patients' ability to receive biomarker testing and treatments.
State-Regulated Illinois Health Plans Subject to Biomarker Test Coverage Mandate Starting 2022
Premium
The law requires state employee, Medicaid, public school, and small employer plans to cover evidence-based biomarker testing, a change that will readily impact cancer patients.

Sutter Health Exploring In-House ctDNA Testing in Effort to Expand Precision Oncology Access
Premium
The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
During an "Investor Day" presentation, company executives presented plans for growing test volumes, increasing market share, and expanding access to underserved populations.
Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering
Premium
Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.